Literature DB >> 2090830

The somatosensory amplification scale and its relationship to hypochondriasis.

A J Barsky1, G Wyshak, G L Klerman.   

Abstract

Forty-one DSM-III-R hypochondriacs and seventy-five randomly chosen patients were obtained from a medical outpatient clinic, and completed a psychiatric diagnostic interview and a ten-item self-report questionnaire, the Somatosensory Amplification Scale (SSAS); The SSAS asks the respondent how much s/he is bothered by various uncomfortable visceral and somatic sensations, most of which are not the pathological symptoms of serious diseases. SSAS scores were normally distributed, and had acceptable test-retest reliability and internal consistency. They were not related to sociodemographic characteristics, or to aggregate medical morbidity. Amplification was significantly higher in the DSM-III-R hypochondriacs than in the comparison sample, and was significantly correlated with the degree of hypochondriacal symptomatology within each sample. In the comparison sample, it was also significantly associated with depressive and anxiety disorders, but not with antisocial personality or substance abuse. The association between the amplification scale and DSM-III-R hypochondriasis remained highly significant after controlling for these concurrent psychiatric disorders.

Entities:  

Mesh:

Year:  1990        PMID: 2090830     DOI: 10.1016/0022-3956(90)90004-a

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  89 in total

1.  Risk factors for chronic pain following breast cancer surgery: a prospective study.

Authors:  Ellen L Poleshuck; Jennifer Katz; Carl H Andrus; Laura A Hogan; Beth F Jung; Dale I Kulick; Robert H Dworkin
Journal:  J Pain       Date:  2006-09       Impact factor: 5.820

2.  Somatic symptom severity among primary care patients who are obese: examining the unique contributions of anxiety sensitivity, discomfort intolerance, and health anxiety.

Authors:  Thomas A Fergus; Christine A Limbers; Jackson O Griggs; Lance P Kelley
Journal:  J Behav Med       Date:  2017-07-14

Review 3.  A biological substrate for somatoform disorders: importance of pathophysiology.

Authors:  Joel E Dimsdale; Robert Dantzer
Journal:  Psychosom Med       Date:  2007-12       Impact factor: 4.312

4.  Participation in a trauma-focused epidemiological investigation may result in sensitization for current health problems.

Authors:  Margot J Verschuur; Philip Spinhoven; Arnold A P van Emmerik; Frits R Rosendaal
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-10-29       Impact factor: 4.328

5.  Somatic symptoms and holistic thinking as major dimensions behind modern health worries.

Authors:  Ferenc Köteles; Péter Simor
Journal:  Int J Behav Med       Date:  2014

6.  Modern health worries, somatosensory amplification and subjective symptoms: a longitudinal study : a longitudinal study.

Authors:  Ferenc Köteles; Péter Simor
Journal:  Int J Behav Med       Date:  2013-03

7.  The relation between sleep and pain among a non-clinical sample of young adults.

Authors:  Serge Brand; Markus Gerber; Uwe Pühse; Edith Holsboer-Trachsler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-03-31       Impact factor: 5.270

8.  Lower-order pain-related constructs are more predictive of cold pressor pain ratings than higher-order personality traits.

Authors:  Jennifer E Lee; David Watson; Laura A Frey Law
Journal:  J Pain       Date:  2010-03-31       Impact factor: 5.820

9.  Attention to bodily sensations and symptom perception in individuals with idiopathic environmental intolerance.

Authors:  Sine Skovbjerg; Robert Zachariae; Alice Rasmussen; Jeanne Duus Johansen; Jesper Elberling
Journal:  Environ Health Prev Med       Date:  2009-12-02       Impact factor: 3.674

10.  Prevalence of Psychiatric Comorbidity in Symptomatic Gastroesophageal Reflux Subgroups.

Authors:  Mustafa Melih Bilgi; Rukiye Vardar; Esra Yıldırım; Baybars Veznedaroğlu; Serhat Bor
Journal:  Dig Dis Sci       Date:  2016-08-26       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.